The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease

Abstract

The most popular type of diabetes is Type-2 diabetes mellitus (T2DM) accounting for 90-95% of diagnosed diabetes and continues to overgrow worldwide and in the USA. This rapid growth may be attributed to the increased elderly population, prevalence of obesity among adults and children, socioeconomic development, urbanization, unhealthy diets, and poor physical activities. The administration of antidiabetic agents in addition to cardio-renal protection is strongly required. Adequate glycemic control must be achieved with protection against cardiovascular and renal outcomes simultaneously. DPP-4 inhibitors are novel antidiabetic agents that have recently demonstrated protection against macro and macrovascular diabetes complications, particularly cardio-renal protection. To evaluate the efficacy and safety of DPP-4 inhibitors on chronic kidney disease patients. We used the PubMed database and searched for relevant articles on the topic. We used the Mesh word searching system; DPP-4 inhibitors; complications; adverse reactions. Type-2 Diabetes mellitus; Chronic kidney disease. DPP-4 inhibitors have demonstrated promising renal protection in healthy animal studies. Nevertheless, in humans with type-2 diabetes mellitus, the renal impact is still controversial. Several randomized clinical trials support the renoprotection effect of diabetic nephropathy.

Evaluation of Drug Prescribing Trends and Drug-Drug Interactions among Chronic Kidney Disease Patients

“…In owning to the confined lifestyle, polypharmacy poses a serious threat of severe adverse effects to patients suffering from CKD. Having different comorbidities like hypertension, Diabetes Mellitus, Coronary artery disease, and infection, and the recommendation of different drugs for the comorbidities can severely worsen the existing CKD complication (Tesfaye et al, 2017;Doody et al, 2020;Alqurashi et al, 2021). In these conditions, rational drug therapy is extremely difficult because of the augmented risk of drug-associated problems that needs the proper attention for the complicated drug regimen with expert monitoring (Al-Ramahi, 2012;Oluyombo et al, 2017).…”